{
    "clinical_study": {
        "@rank": "3073", 
        "acronym": "MRSI+RRP", 
        "arm_group": [
            {
                "arm_group_label": "High risk prostate cancer patients", 
                "description": "Men who have been recently diagnosed with high risk prostate cancer (Gleason score 7 and above) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health & Science University's Advanced Imaging Research Center."
            }, 
            {
                "arm_group_label": "Low risk prostate cancer patients", 
                "description": "Men who have been recently diagnosed with low risk prostate cancer (Gleason score 7 [3+4] and below) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health & Science University's Advanced Imaging Research Center."
            }
        ], 
        "biospec_descr": {
            "textblock": "Blood, Urine, Prostatic fluid and Prostatectomy tissue"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "A prostate cancer diagnosis starts a list of events that often leads to fast-moving\n      treatment, thought by many to result in vast over-treatment of this disease. So, discovery\n      of different diagnostic methods that allow clinicians to identify slow-growing from\n      potentially fast-growing disease prior to or at the time of prostate biopsy could result in\n      early and suitable treatment for men at greatest risk, while greatly decreasing the number\n      of biopsies, surgical procedures, hormonal and chemotherapeutic treatments, cost, and\n      patient worry, for those with more slow-growing disease."
        }, 
        "brief_title": "Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Prostate cancer diagnosis prior to treatment\n\n          -  Age 21 years or older\n\n          -  Signed informed subject consent\n\n          -  Prostatectomy as planned prostate cancer treatment\n\n        Exclusion Criteria:\n\n          -  Men who do not choose prostatectomy\n\n          -  Men who have undergone any neoadjuvant therapy\n\n          -  Men who have cardiac pacemakers or other implanted electronic devices\n\n          -  Men who have any surgically implanted metal\n\n          -  Men who have had any surgical procedure that precludes placement of endorectal probe\n\n          -  Indication of dementia or memory issues listed on problem list\n\n          -  Men who indicate exposure to ocular metal fragments; confirmed by positive ocular\n             x-ray\n\n          -  Men who are taking newly-prescribed (within 6 months of enrollment) lipid control\n             medications"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "all men newly-diagnosed with prostate cancer at the Portland VA and OHSU Urology clinics"
            }
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01780701", 
            "org_study_id": "PC110361/ PC110361P1", 
            "secondary_id": [
                "W81XWH-12-1-0168", 
                "2978", 
                "8458", 
                "Log #A-17208"
            ]
        }, 
        "intervention": {
            "arm_group_label": [
                "High risk prostate cancer patients", 
                "Low risk prostate cancer patients"
            ], 
            "intervention_name": "Magnetic Resonance Spectroscopy Imaging with rectal probe", 
            "intervention_type": "Procedure", 
            "other_name": [
                "Magnetic Resonance Spectroscopy Imaging", 
                "MRSI", 
                "Magnetic Resonance Imaging", 
                "MRI"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "prostate cancer aggressiveness", 
            "magnetic resonance imaging", 
            "fatty acid synthase"
        ], 
        "lastchanged_date": "March 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97207"
                    }, 
                    "name": "Portland VA Medical Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Jackilen Shannon, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Mark Garzotto, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "George Thomas, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Oregon Health & Science University Advanced Imaging Research Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Jonathan Q Purnell, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "William Rooney, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Xin Li, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Imaging Prostatic Lipids to Distinguish Aggressive Prostate Cancer", 
        "other_outcome": {
            "description": "To quantify the association between key metabolic intermediates involved in lipid metabolism, mitochondrial function, inflammation, and apoptosis in prostatectomy samples and fatty acid synthase protein expression, intraprostatic lipid and tumor aggressiveness.", 
            "measure": "Number of participants with accumulation of lipid intermediates and proteins", 
            "safety_issue": "No", 
            "time_frame": "Up to 3 years"
        }, 
        "overall_contact": {
            "email": "shannoja@ohsu.edu", 
            "last_name": "Jackilen Shannon, PhD", 
            "phone": "503-220-8262", 
            "phone_ext": "57285"
        }, 
        "overall_contact_backup": {
            "email": "farrisp@ohsu.edu", 
            "last_name": "Paige E Farris, MSW", 
            "phone": "503-220-8262", 
            "phone_ext": "54868"
        }, 
        "overall_official": [
            {
                "affiliation": "Oregon Health and Science University", 
                "last_name": "Jackilen Shannon, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Oregon Health and Science University", 
                "last_name": "Jonathan Q Purnell, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Determine the correlation between the amount of intraprostatic lipid using 1H (proton) magnetic resonance spectroscopic imaging (MRSI) with an endorectal coil obtained prior to prostatectomy with fatty acid synthase protein expression measured in benign and cancer tissue from prostatectomy samples.", 
            "measure": "Number of participants with increased intraprostatic lipid concentration", 
            "safety_issue": "No", 
            "time_frame": "Up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01780701"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Identify the association between fatty acid synthase protein expression in prostatectomy samples, intraprostatic lipid as measured by 1H MRSI, and prostate tumor aggressiveness.", 
            "measure": "Number of participants with increased tumor aggressiveness", 
            "safety_issue": "No", 
            "time_frame": "Up to 3 years"
        }, 
        "source": "OHSU Knight Cancer Institute", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Department of Defense", 
                    "agency_class": "U.S. Fed"
                }, 
                {
                    "agency": "Portland VA Medical Center", 
                    "agency_class": "U.S. Fed"
                }, 
                {
                    "agency": "Oregon Health and Science University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "OHSU Knight Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Case-Crossover, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}